Overview

PET Study With [89Zr]-Df-CriPec® Docetaxel

Status:
Completed

Trial end date:
2020-05-08

Target enrollment:

Participant gender:

Summary

A clinical phase I, open-label PET study with [89Zr]-Df-CriPec® docetaxel in patients with solid tumours to assess biodistribution and tumour accumulation of [89Zr]-Df-CriPec® docetaxel.

Phase:

Phase 1

Details

Lead Sponsor:

VU University Medical Center

Collaborator:

Cristal Therapeutics

Treatments:

Docetaxel